27Mar2017 Avillion Strengthens Clinical and Regulatory Development Capabilities with the Appointment of Mark Weinberg as Chief Medical Officer
06Dec2016 Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
15Sep2015 Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
09Jan2014 Avillion group partners with Pfizer to co-develop Bosulif (bosutinib) as first-line treatment